Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2009-05-26
2010-12-14
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S190100, C424S192100, C435S069100, C435S069700, C536S023700
Reexamination Certificate
active
07850980
ABSTRACT:
The present invention provides purified and isolated polynucleotide molecules that encodeChlamydiapolypeptides which can be used in methods to prevent, treat, and diagnoseChlamydiainfection. In one form of the invention, the polypeptides relate to the 98 KDa OMP antigen designated CPN100686 RY 54 (SEQ ID No:14, encoded in one form by SEQ ID NO:1).
REFERENCES:
patent: 6521745 (2003-02-01), Murdin et al.
patent: 6559294 (2003-05-01), Griffais et al.
patent: 6693087 (2004-02-01), Murdin et al.
patent: 6808713 (2004-10-01), Murdin et al.
patent: 6822071 (2004-11-01), Stephens et al.
patent: 7019125 (2006-03-01), Murdin et al.
patent: 7070792 (2006-07-01), Murdin et al.
patent: 7081245 (2006-07-01), Murdin et al.
patent: 2002/0082402 (2002-06-01), Murdin et al.
patent: 2002/0094340 (2002-07-01), Murdin et al.
patent: 2002/0094965 (2002-07-01), Murdin et al.
patent: 2002/0099188 (2002-07-01), Murdin et al.
patent: 2002/0132994 (2002-09-01), Murdin et al.
patent: 2003/0100706 (2003-05-01), Murdin et al.
patent: 2004/0254130 (2004-12-01), Murdin et al.
patent: 0784059 (1997-07-01), None
patent: WO 99/27105 (1999-06-01), None
patent: WO 00/27994 (2000-05-01), None
U.S. Appl. No. 09/857,128, filed Sep. 20, 2001, Murdin et al.
U.S. Appl. No. 09/471,194, filed Dec. 23, 1999, Murdin et al.
U.S. Appl. No. 09/523,647, filed Mar. 10, 2000, Murdin et al.
U.S. Appl. No. 09/522,606, filed Mar. 10, 2000, Murdin et al.
U.S. Appl. No. 09/609,243, filed Jun. 30, 2000, Murdin et al.
U.S. Appl. No. 09/662,813, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/663,362, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/663,360, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/663,361, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/662,814, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/662,812, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/709,473, filed Nov. 13, 2000, Murdin et al.
U.S. Appl. No. 09/709,474, filed Nov. 13, 2000, Murdin et al.
U.S. Appl. No. 09/709,384, filed Nov. 13, 2000, Murdin et al.
U.S. Appl. No. 09/747,349, filed Dec. 22, 2000, Murdin et al.
Niman et al., PNAS USA, 1983, vol. 80: 4949-4953.
Current Protocols in Immunology, 1997, unit 9.7.1, 9.7.5, 9.7.16, 9.7.19.
Reece et al., 1994 J. Immunol., vol. 172, 241-254.
Hillier et al., Genome Research, vol. 6, No. 9, pp. 807-828, 1996.
Allen et al., Journal of Immunology, 1991, 147, 674-679.
Batteiger et al., 1996, Infection and Immunity, 64, 2839-2841.
Murdin et al., J. Infectious Diseases, 2000, 181, Suppl. 3: S552-S557.
Verma et al., 1997, Nature, vol. 389, p. 239.
Miller et al., The FASB Journal, 1995, 9: 190-199.
Rudinger et al., in “Peptide Hormones”, edited by Parsons, J.A., University Park Press, Jun. 1976, p. 6.
Burgess et al., The Journal of Cell Biology, 111: 2129-2138, 1990.
Lazar et al., Molecular and Cellular Biology, 8(3), 1247-1252, 1988.
Jobling et al., Mol. Microbiol., 1991, 5(7): 1755-1767.
Howard R.F., Jacobson K.C., Rickel E., Thurman, Analysis of inhibitory epitopes in thePlasmodium falciparumrhoptry protein RAP-1 including identification of a second inhibitory epitope, J. Infect. Immun., Jan. 1998, 66(1): 380-6 (abstract).
AbD Serotec Excerpt from technical brochure from www.ab-direct.com, 2009.
Ayyildiz, Technical Approach to Generate Polyclonal Antibodies against Bacterially expressed GST-PYK-C, Tr. J. Medical Services, 29 (1999), 355-360 (abstract).
Cassill J.A., Whitney M., Jaozeiro C.A., Becker A., Zuker C.S., Isolation ofDrosophilagenes encoding G protein-coupled receptor kinases, Proc. Nat. Acad. Sci. USA, Dec. 15, 1991, 88(24): 11067-70 (pp. 11067 and 11068).
Lutzelschwab R., Klambt C., Rossa R., Schmidt O., A Protein Product of theDrasophilarecessive tumor gene, 1(2) giant gl, potentially has cell adhesion properties, EMBO J., Jun. 1987, 6(6): 1791-1797 (pp. 1791 and 1792).
Schoneck R, Plumas-Marty B, Taibi A, Billaut-Mulot O, Loyens M, Gras-Masse H, Capron A, Ouassi A,Trypanosoma cruzicDNA encodes a tandemly repeated domain structure characteristic of small stress proteins an glutathione S-transferases, Biol Cell., 1994, 80(1): 1-10, (pp. 1 and 2).
Philippe B, Brion JP, Coppens E, Octave JN, Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein, J. Neurosci. Res., Dec. 15, 1996, 46(6): 709-19 (abstract).
Yu H, Nakano Y, Yamashita Y, Oho T and Koga T, Effects of antibodies against cell surface protein antigen PA-c-glucosyltransferase fusion proteins on glucan synthesis and cell adhesion ofStreptococcus mutans, Infect. Immunol., Jun. 1997, 2292-2298, vol. 65, No. 6 (Abstract).
Zhou FC, Xu Y, Bledsoe S, Lin R, Kelley MR, Serotonin transporter antibodies: production, characteristic, and localization in the brain, Brain Res. Mol. Brain Res., Dec. 31, 1996, 43(1-2): 267-78, (Abstract).
Boehringer Mannheim Biochemicals (1991 Catalog p. 557).
Stratagene (1991 Product Catalog, p. 66).
Promega (1993/1994 catalog, pp. 90-91), or New England Biolabs (catalog 1986/1987, pp. 60-62).
Gibco BRL (Catalogue & Reference Guide 1992, p. 292).
Grayston et al. (1995) Journal of Infectious Diseases 168:1231.
Campos et al. (1995) Investigation of Ophthalmology and Visual Science 36:1477.
Grayston et al. (1990) Journal of Infectious Diseases 161: 618.
Marrie (1993) Clinical Infectious Diseases. 18:501.
Wang et al. (1986) Chamydial Infections. Cambridge University Press, Cambridge. p. 329.
Saikku et al. (1988) Lancet; ii:983.
Thom et al. (1992) JAMA 268:68.
Linnanmaki et al. (1993) Circulation 87: 1130.
Saikku et al. (1992) Annals Internal Medicine 116:499.
Melnick et al. (1993) American Journal of Medicine 95: 499.
Shor et al. (1992) South African Medical Journal 82: 158.
Kuo et al. (1993) Journal of Infectious Diseases 167:841.
Kuo et al. (1993) Arteriosclerosis and Thrombosis 13: 1501.
Campbell et al. (1995) Journal of Infectious Diseases 172:585.
Chiu et al (1997) Circulation. 96(7) :2144-2148.
Ramirez et a). (1996) Annals of Internal Medicine 125:979.
Jackson et al. Abst. K121, p272, 36th ICAAC, Sep. 15-18, 1996, New Orleans.
Fong et al. (1997) Journal of Clinical Microbiolology 35:48.
Hahn DL, et al. Evidence forChlamydia pneumoniaeinfection in steroid-dependent asthma. Ann Allergy Asthma Immunol. Jan. 1998; 80(1): 45-49.
Hahn DL, et al. “Association ofChlamydia pneumoniaeIgA antibodies with recently symptomatic asthma”. Epidemiol Infect. Dec. 1996; 117(3): 513-517.
Bjornsson E, at al. Serology ofChlamydiain relation to asthma and bronchial hyperresponsiveness Scand .7 Infect Dis. 1956; 28(1): 63-69.
Hahn DL. “Treatment ofChlamydia pneumoniaeinfection in adult asthma: a before-after trial” J Fam Pract. Oct. 1995; 41(4):345-351.
Allegra L. et al., “Acute exacerbations of asthma in adults: Role ofChlamydia pneumoniaeinfection”, Eur Respir J Dec. 1994, 7(12) 2165-2168.
Hahn DL, et al. Association ofChlamydia pneumoniae(strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma JAMA. Jul. 10, 1991; 266(2): 225-230.
Pal et al. (1996) Infection and Immunity.64:5341.
Jones et al. (1995) Vaccine 13:715.
Igietseme et al (1993) Regional Immunology 5:317.
Magee et al (1993) Regional Immunology 5: 305.
Landers et al (1991) Infection & Immunity 59:3774.
Magee et al (1995) Infection & Immunity 63:516.
Cotter et al. (1995) Infection and Immunity 63:4704.
Campbell et al. (1990) Infection and Immunity 58:93.
McCafferty et al (1995) Infection and Immunity 63:2387-9.
Gaydos et al. Similarity ofChlamydia pneumonlaestrains in the Variable Domain IV Region of the Major Outer Membrane Protein Gene; Infection and Immunity; 60(12) :5319-5323. Dec. 1992.
Wiedmann-Al-Ahmad M, et al. “Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein ofChlamydia pneumoniae” Clin Diagn lab Immunol. Nov. 1997; 4(6:700-704).
Hughes et al., 1992. Infect. Immun. 60(9) :3497.
Dion et al., 1990. Virology 179:474-477.
Snijders et al., 1991. J. Gen. Virol. 72:557-56
Murdin Andrew D.
Oomen Raymond P.
Wang Joe
Baskar Padma V
Mondesi Robert B
Sanofi Pasteur Limited
LandOfFree
Chlamydia OMP antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chlamydia OMP antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlamydia OMP antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151485